About Neurona Therapeutics
Neurona Therapeutics is a company based in San Francisco (United States) founded in 2008 by Cory R. Nicholas was acquired by UCB in April 2026. Neurona Therapeutics has raised $417.69 million across 9 funding rounds from investors including Fidelity Investments, ARE and UCB. The company has 67 employees as of December 31, 2022. Neurona Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter San Francisco, United States
- Employees 67 as on 31 Dec, 2022
- Founders Cory R. Nicholas
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neurona Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$417.69 M (USD)
in 9 rounds
-
Latest Funding Round
$102 M (USD), Series E
Mar 28, 2025
-
Investors
Fidelity Investments
& 15 more
-
Employee Count
67
as on Dec 31, 2022
-
Acquired by
UCB
(Apr 21, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Neurona Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Neurona Therapeutics
Neurona Therapeutics has successfully raised a total of $417.69M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $102 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neurona Therapeutics
Neurona Therapeutics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, ARE and UCB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Neurona Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neurona Therapeutics
Investment portfolio details for Neurona Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neurona Therapeutics
Detailed financials for Neurona Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neurona Therapeutics Comparisons
Peer comparison for Neurona Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neurona Therapeutics
Neurona Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of Neurona Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neurona Therapeutics
Complete news archive for Neurona Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neurona Therapeutics
Neurona Therapeutics was founded in 2008.
Neurona Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Cory R. Nicholas is the current CEO of Neurona Therapeutics. They have also founded this company.
Neurona Therapeutics is a funded company, having raised a total of $417.69M across 9 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Neurona Therapeutics is 67.
Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.
Neurona Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Neurona Therapeutics has 16 investors. Key investors include Fidelity Investments, ARE, UCB, Schroders, and The Column Group.